Get Involved
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Study Purpose
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:- - Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma.
- - Has not received any prior systemic therapy for their melanoma beyond surgical resection.
- - No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab.
- - Is disease free at the time of providing documented consent for the study.
- - Human immunodeficiency virus (HIV)-infected participants must have well controlled
HIV on anti-retroviral therapy (ART)
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following: - Has ocular or mucosal melanoma.
- - Has cancer that has spread to other parts of the body and cannot be removed with surgery.
- - Has heart failure within the past 6 months.
- - Has received prior cancer therapy or another cancer vaccine.
- - Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years.
- - Has severe reaction to study medications or any of their substance used to prepare a drug.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05933577 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Merck Sharp & Dohme LLC |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Medical Director |
| Principal Investigator Affiliation | Merck Sharp & Dohme LLC |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Poland, Portugal, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Melanoma |
| Study Website: | View Trial Website |
Arms
Experimental: Intismeran autogene + Pembrolizumab
Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
Active Comparator: Placebo + Pembrolizumab
Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
Interventions
Biological: - Intismeran autogene
IM injection
Biological: - Pembrolizumab
IV infusion
Other: - Placebo
IM injection
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Highlands Oncology Group ( Site 1943)
Springdale 4132093, Arkansas 4099753, 72762
Status
Address
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918)
Los Angeles 5368361, California 5332921, 90095
Status
Address
UCSF Medical Center at Mission Bay ( Site 1929)
San Francisco 5391959, California 5332921, 94158
Status
Address
Yale-New Haven Hospital-Yale Cancer Center ( Site 1933)
New Haven 4839366, Connecticut 4831725, 06510
Status
Address
Orlando Health Cancer Institute ( Site 1937)
Orlando 4167147, Florida 4155751, 32806
Status
Address
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945)
Tampa 4174757, Florida 4155751, 33612
Status
Address
Winship Cancer Institute of Emory University ( Site 1940)
Atlanta 4180439, Georgia 4197000, 30322
Status
Address
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950)
Marietta 4207783, Georgia 4197000, 30060
Status
Address
University of Iowa-Holden Comprehensive Cancer Center ( Site 1935)
Iowa City 4862034, Iowa 4862182, 52242
Status
Address
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912)
Baltimore 4347778, Maryland 4361885, 21287
Status
Address
Massachusetts General Hospital ( Site 1927)
Boston 4930956, Massachusetts 6254926, 02114
Status
Address
Beth Israel Deaconess Medical Center ( Site 1957)
Boston 4930956, Massachusetts 6254926, 02215
Status
Address
Dana-Farber Cancer Institute ( Site 1956)
Boston 4930956, Massachusetts 6254926, 02215
Status
Address
University of Michigan ( Site 1915)
Ann Arbor 4984247, Michigan 5001836, 48109
Status
Address
Cancer and Hematology Centers of Western Michigan ( Site 1932)
Grand Rapids 4994358, Michigan 5001836, 49503
Status
Address
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944)
Hackensack 5098706, New Jersey 5101760, 07601
Status
Address
Atlantic Health System ( Site 1925)
Morristown 5101427, New Jersey 5101760, 07960
Status
Address
Valley Health Systems - Ridgewood Campus ( Site 1947)
Ridgewood 5103269, New Jersey 5101760, 07450
Status
Address
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958)
Mineola 5127134, New York 5128638, 11501
Status
Address
NYU Langone Health-Perlmutter Cancer Center ( Site 1917)
New York 5128581, New York 5128638, 10016
Status
Address
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical
New York 5128581, New York 5128638, 10032
Status
Address
Memorial Sloan Kettering Cancer Center ( Site 1914)
New York 5128581, New York 5128638, 10065
Status
Address
University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949)
Chapel Hill 4460162, North Carolina 4482348, 27599
Status
Address
Duke Cancer Institute ( Site 1911)
Durham 4464368, North Carolina 4482348, 27710
Status
Address
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905)
Philadelphia 4560349, Pennsylvania 6254927, 19104
Status
Address
UPMC Hillman Cancer Center ( Site 1909)
Pittsburgh 5206379, Pennsylvania 6254927, 15232
Status
Address
Medical University of South Carolina-Hollings Cancer Center ( Site 1934)
Charleston 4574324, South Carolina 4597040, 29425
Status
Address
Sanford Cancer Center ( Site 1951)
Sioux Falls 5231851, South Dakota 5769223, 57104
Status
Address
SCRI Oncology Partners ( Site 1910)
Nashville 4644585, Tennessee 4662168, 37203
Status
Address
Texas Oncology - Austin ( Site 1903)
Austin 4671654, Texas 4736286, 78731
Status
Address
Texas Oncology - Dallas (Sammons) ( Site 1902)
Dallas 4684888, Texas 4736286, 75246
Status
Address
University of Texas MD Anderson Cancer Center ( Site 1920)
Houston 4699066, Texas 4736286, 77030
Status
Address
Inova Schar Cancer Institute ( Site 1900)
Fairfax 4758023, Virginia 6254928, 22031
Status
Address
Fred Hutchinson Cancer Center ( Site 1901)
Seattle 5809844, Washington 5815135, 98109
International Sites
Status
Address
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202)
CABA, Buenos Aires 3435907, C1199ABB
Status
Address
Instituto Alexander Fleming-Alexander Fleming ( Site 2203)
Buenos Aires 3435910, Buenos Aires F.D. 3433955, 1426
Status
Address
Centro Privado de RMI Río Cuarto S.A. II ( Site 2201)
Río Cuarto 3838874, Córdoba Province 3860255, X5800ALB
Status
Address
Hospital Aleman ( Site 2200)
Buenos Aires 3435910, , C1118AAT
Status
Address
Sanatorio Finochietto ( Site 2205)
Buenos Aires 3435910, , C1187AAN
Status
Address
Clinica Adventista Belgrano-Oncology ( Site 2204)
Caba, , 1430
Status
Address
Westmead Hospital-Department of Medical Oncology ( Site 1001)
Westmead 2143973, New South Wales 2155400, 2145
Status
Address
Melanoma Institute Australia-Clinical Trials Unit ( Site 1000)
Wollstonecraft 9972972, New South Wales 2155400, 2065
Status
Address
Princess Alexandra Hospital ( Site 1003)
Brisbane 2174003, Queensland 2152274, 4102
Status
Address
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1005)
Melbourne 2158177, Victoria 2145234, 3000
Status
Address
Paula Fox Melanoma & Cancer Centre ( Site 1004)
Melbourne 2158177, Victoria 2145234, 3004
Status
Address
One Clinical Research ( Site 1002)
Nedlands 2064874, Western Australia 2058645, 6009
Status
Address
UZ Brussel-Medische oncologie ( Site 3405)
Brussels 2800866, Bruxelles-Capitale, Region de, 1090
Status
Address
Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3402)
Genk 2797670, Limburg, 3600
Status
Address
UZ Gent ( Site 3403)
Ghent 2797656, Oost-Vlaanderen, 9000
Status
Address
UZ Leuven ( Site 3400)
Leuven 2792482, Vlaams-Brabant, 3000
Status
Address
AZ Groeninge Campus Kennedylaan-Oncology ( Site 3401)
Kortrijk 2794055, West-Vlaanderen, 8500
Status
Address
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 2303)
Belo Horizonte 3470127, Minas Gerais 3457153, 30130-090
Status
Address
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 2302)
Ijuí 3461444, Rio Grande do Sul 3451133, 98700-000
Status
Address
Hospital Nossa Senhora da Conceição ( Site 2309)
Porto Alegre 3452925, Rio Grande do Sul 3451133, 91350-200
Status
Address
Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC II ( Site 2305)
Rio de Janeiro 3451190, , 20220-410
Status
Address
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)
São Paulo 3448439, , 01246-000
Status
Address
Cross Cancer Institute ( Site 1104)
Edmonton 5946768, Alberta 5883102, T6G 1Z2
Status
Address
BC Cancer Vancouver-Clinical Trials Unit ( Site 1106)
Vancouver 6173331, British Columbia 5909050, V5Z 4E6
Status
Address
William Osler Health System ( Site 1105)
Brampton 5907364, Ontario 6093943, L6R 3J7
Status
Address
Sunnybrook Research Institute ( Site 1103)
Toronto 6167865, Ontario 6093943, M4N 3M5
Status
Address
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 1102)
Toronto 6167865, Ontario 6093943, M5G 2M9
Status
Address
Centre Hospitalier de l'Université de Montréal-Unité de Recherche Clinique en Oncologie et Hématolo
Montreal 6077243, Quebec 6115047, H2X 0X9
Status
Address
Centre intégré de cancérologie du CHU de Québec Université L-Hemato-Oncology ( Site 1101)
Québec 6325494, Quebec 6115047, G1J 1Z4
Status
Address
FALP-UIDO ( Site 2400)
Santiago 3871336, Region M. de Santiago, 7500921
Status
Address
Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 2402)
Santiago 3871336, Region M. de Santiago, 7620002
Status
Address
Bradfordhill ( Site 2401)
Santiago 3871336, Region M. de Santiago, 8420383
Status
Address
Clinica Somer-Unidad de Investigacion y Docencia ( Site 2506)
Rionegro 3670730, Antioquia 3689815, 054040
Status
Address
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2500)
Bogotá 3688689, Bogota D.C. 3688685, 111321
Status
Address
Oncomedica S.A.S ( Site 2503)
Montería 3674453, Departamento de Córdoba 3685889, 230002
Status
Address
Fundación Valle del Lili ( Site 2505)
Santiago de Cali 3687925, Valle del Cauca Department 3666313, 760032
Status
Address
Herlev and Gentofte Hospital ( Site 3301)
Copenhagen 2618425, Capital Region 6418538, 2730
Status
Address
Aalborg Universitetshospital, Syd ( Site 3302)
Aalborg 2624886, North Denmark 6418540, 9000
Status
Address
Odense Universitetshospital ( Site 3300)
Odense C 11746507, Region Syddanmark 6418542, 5000
Status
Address
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 1211)
Nice 2990440, Alpes-Maritimes, 06200
Status
Address
Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi
Marseille 2995469, Bouches-du-Rhone, 13385
Status
Address
Centre Georges François Leclerc ( Site 1210)
Dijon 3021372, Cote-d Or, 21079
Status
Address
CHU Besançon ( Site 1209)
Besançon 3033123, Doubs, 25030
Status
Address
CHU de Bordeaux Hop St ANDRE-Service de Dermatologie ( Site 1204)
Bordeaux 3031582, Gironde, 33075
Status
Address
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1206)
Rennes 2983990, Ille-et-Vilaine, 35042
Status
Address
Hopital Claude Huriez - CHU de Lille ( Site 1207)
Lille 2998324, Nord, 59037
Status
Address
centre hospitalier lyon sud-Service de dermatologie ( Site 1202)
Pierre-Bénite 2987314, Rhone, 69310
Status
Address
CHU d'Amiens-Picardie - Hôpital Sud-Dermatologie ( Site 1208)
Amiens 3037854, Somme, 80054
Status
Address
Gustave Roussy-Dermatologie ( Site 1201)
Villejuif 2968705, Val-de-Marne, 94800
Status
Address
Hôpital Saint-Louis ( Site 1200)
Paris 2988507, , 75010
Status
Address
Universitätsmedizin Mannheim ( Site 1305)
Mannheim 2873891, Baden-Wurttemberg 2953481, 68167
Status
Address
Universitaetsklinikum Augsburg ( Site 1312)
Augsburg 2954172, Bavaria 2951839, 86156
Status
Address
Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 1315)
München 2867713, Bavaria 2951839, 80337
Status
Address
Universitätsmedizin Göttingen - Georg-August-Universität-Dermatology ( Site 1308)
Göttingen 2918632, Lower Saxony 2862926, 37075
Status
Address
Universitätsmedizin Rostock-Klinik und Poliklinik für Dermatologie und Venerologie ( Site 1310)
Rostock 2844588, Mecklenburg-Vorpommern 2872567, 18057
Status
Address
Universitaetsklinikum Koeln ( Site 1307)
Cologne 2886242, North Rhine-Westphalia 2861876, 50937
Status
Address
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 1300)
Essen 2928810, North Rhine-Westphalia 2861876, 45147
Status
Address
Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 1301)
Minden 2871039, North Rhine-Westphalia 2861876, 32429
Status
Address
Universitaetsklinikum des Saarlandes ( Site 1313)
Homburg 2899449, Saarland 2842635, 66424
Status
Address
SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1306)
Gera 2921232, Thuringia 2822542, 07548
Status
Address
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 1302)
Berlin 2950159, , 10115
Status
Address
Universitaetsklinikum Hamburg-Eppendorf ( Site 1309)
Hamburg 2911298, , 20246
Status
Address
General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 3700)
Athens 264371, Attica 6692632, 115 26
Status
Address
Metropolitan Hospital-A' Oncology Dpt ( Site 3701)
Neo Faliro 256495, Attica 6692632, 185 47
Status
Address
Bioclinic Thessalonikis Private Clinic Single Member S.A.-Oncology ( Site 3703)
Thessaloniki 734077, Central Macedonia 6697801, 546 22
Status
Address
European Interbalkan Medical Center-Oncology Department ( Site 3702)
Thessaloniki 734077, , 57001
Status
Address
Emek Medical Center ( Site 2003)
Afula 295740, , 1834111
Status
Address
Hadassah Medical Center ( Site 2004)
Jerusalem 281184, , 9112001
Status
Address
Rabin Medical Center ( Site 2000)
Petah Tikva 293918, , 4941492
Status
Address
Sheba Medical Center ( Site 2001)
Ramat Gan 293788, , 5265601
Status
Address
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401)
Milan 3173435, Lombardy 3174618, 20133
Status
Address
Istituto Europeo di Oncologia IRCCS ( Site 1404)
Milan 3173435, Lombardy 3174618, 20141
Status
Address
Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 1402)
Siena 3166548, Tuscany 3165361, 53100
Status
Address
AO Santa Maria della Misericordia ( Site 1403)
Perugia 3171180, Umbria 3165048, 06129
Status
Address
Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi
Napoli 9031661, , 80131
Status
Address
Nagoya University Hospital ( Site 4201)
Nagoya 1856057, Aichi-ken 1865694, 466-8560
Status
Address
Shizuoka Cancer Center ( Site 4202)
Nagaizumi-cho,Sunto-gun, Shizuoka 1851715, 411-8777
Status
Address
National Cancer Center Hospital ( Site 4200)
Chūō 13353695, Tokyo 1850144, 104-0045
Status
Address
Capital, Coast and Hutt Valley District - Wellington Regional Hospital ( Site 1502)
Newtown 6244789, Wellington Region 2179538, 6021
Status
Address
Harbour Cancer & Wellness ( Site 1500)
Auckland 2193733, , 1023
Status
Address
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2909)
Poznan 3088171, Greater Poland Voivodeship 3337498, 60-569
Status
Address
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2908)
Bydgoszcz 3102014, Kuyavian-Pomeranian Voivodeship 3337500, 85-796
Status
Address
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2903)
Siedlce 759412, Masovian Voivodeship 858787, 08-110
Status
Address
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warsaw 756135, Masovian Voivodeship 858787, 02-781
Status
Address
Bialostockie Centrum Onkologii ( Site 2905)
Bialystok 776069, Podlaskie Voivodeship 858789, 15-027
Status
Address
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site
Gdansk 3099434, Pomeranian Voivodeship 3337496, 80-214
Status
Address
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2907)
Gliwice 3099230, Silesian Voivodeship 3337497, 44-101
Status
Address
Zachodniopomorskie Centrum Onkologii ( Site 2904)
Szczecin 3083829, West Pomeranian Voivodeship 3337499, 71-730
Status
Address
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch
Kielce 769250, Świętokrzyskie Voivodeship 858790, 25-734
Status
Address
Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3601)
Lisbon 2267057, Lisbon District 2267056, 1099-023
Status
Address
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3603)
Lisbon 2267057, Lisbon District 2267056, 1649-035
Status
Address
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3602)
Lisbon 2267057, , 1449-005
Status
Address
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3604)
Porto 2735943, , 4200-072
Status
Address
Medical Oncology Centre of Rosebank ( Site 4106)
Johannesburg 993800, Gauteng 1085594, 2196
Status
Address
Wilgers Oncology Centre ( Site 4103)
Pretoria 964137, Gauteng 1085594, 0040
Status
Address
Cape Town Oncology Trials ( Site 4100)
Cape Town 3369157, Western Cape 1085599, 7570
Status
Address
Kyungpook National University Chilgok Hospital-Hematology/oncology ( Site 3904)
Daegu 1835329, Taegu-Kwangyokshi, 41404
Status
Address
Chungnam national university hospital-Department of Internal Medicine ( Site 3903)
Daejeon 1835235, Taejon-Kwangyokshi, 35015
Status
Address
Seoul National University Hospital-Oncology ( Site 3902)
Seoul 1835848, , 03080
Status
Address
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3901)
Seoul 1835848, , 03722
Status
Address
Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)
Seoul 1835848, , 06351
Status
Address
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
Barcelona 3128760, Catalonia 3336901, 08036
Status
Address
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1603)
Pozuelo de Alarcón 3112989, Madrid 3117732, 28223
Status
Address
Hospital Universitario Ramón y Cajal ( Site 1602)
Madrid 3117735, Madrid, Comunidad de, 28034
Status
Address
H.R.U Málaga - Hospital General-Oncology ( Site 1605)
Málaga 2514256, Malaga, 29011
Status
Address
HOSPITAL CLINICO DE VALENCIA ( Site 1604)
Valencia 2509954, Valenciana, Comunitat, 46010
Status
Address
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1601)
Barcelona 3128760, , 08035
Status
Address
Skånes Universitetssjukhus Lund ( Site 3201)
Lund 2693678, Skåne County 3337385, 22185
Status
Address
Sahlgrenska Universitetssjukhuset ( Site 3200)
Gothenburg 2711537, Västra Götaland County 3337386, 413 45
Status
Address
UniversitätsSpital Zürich-Dermatology ( Site 1700)
Zürich Flughafen, Canton of Zurich 2657895, 8058
Status
Address
Kantonsspital Graubünden-Medizin ( Site 1703)
Chur 2661169, Kanton Graubünden 2660522, 7000
Status
Address
Chang Gung Memorial Hospital at Kaohsiung (Site 4000)
Kaohsiung City 1673820, , 83301
Status
Address
National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004)
Tainan City 1668355, , 704
Status
Address
National Taiwan University Hospital (Site 4001)
Taipei 1668341, , 10002
Status
Address
Chang Gung Medical Foundation-Linkou Branch ( Site 4003)
Taoyuan District 1667905, , 33305
Status
Address
Hacettepe Universite Hastaneleri ( Site 3006)
Ankara 323786, , 06230
Status
Address
Memorial Ankara Hastanesi-Medical Oncology ( Site 3010)
Ankara 323786, , 06520
Status
Address
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3002)
Ankara 323786, , 06800
Status
Address
Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 3008)
Istanbul 745044, , 34303
Status
Address
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3003)
Istanbul 745044, , 34722
Status
Address
Ege University Medical Faculty Hospital ( Site 3011)
Izmir 311046, , 35100
Status
Address
I.E.U. Medical Point Hastanesi-Oncology ( Site 3005)
Izmir 311046, , 35575
Status
Address
Bristol Haematology and Oncology Centre ( Site 1811)
Bristol 2654675, Bristol, City of, BS2 8ED
Status
Address
Addenbrooke's Hospital ( Site 1800)
Cambridge 2653941, Cambridgeshire, CB2 2QQ
Status
Address
Norfolk and Norwich University Hospitals NHS Foundation Trust ( Site 1813)
Cringleford 2651971, England 6269131, NR4 7UY
Status
Address
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1804)
London 2643743, Kensington and Chelsea, SW3 6JJ
Status
Address
University College London Hospital ( Site 1807)
London 2643743, London, City of, NW1 2PG
Status
Address
Western General Hospital ( Site 1806)
Edinburgh 2650225, Midlothian, EH4 2XU
Status
Address
The Churchill Hospital ( Site 1805)
Oxford 2640729, Oxfordshire, OX3 7LE
Status
Address
St James's University Hospital-Leeds Cancer Centre ( Site 1808)
Leeds 2644688, , LS9 7TF
Status
Address
The Christie NHS Foundation Trust ( Site 1814)
Manchester 2643123, , m20 4bx
